📊 WHY DATA ANALYSIS MATTERS
Rigorous data analysis transforms raw experimental outputs into actionable insights. Proper statistical methods ensure reproducibility, enable meaningful compound comparisons, and satisfy regulatory requirements for alternative method qualification. Poor analysis leads to false positives, failed replication, and regulatory rejection.
PREREQUISITES
Required Knowledge
- Basic statistics (mean, SD, SEM, CV%)
- Hypothesis testing (t-test, ANOVA)
- Non-linear regression concepts
- Understanding of biological vs technical replicates
- Quality control metrics (Z-factor)
Data Requirements
- Raw data in machine-readable format (CSV, Excel)
- Plate layouts with sample identifiers
- Vehicle and positive control data
- Metadata (dates, operators, lot numbers)
- At least 3 biological replicates per condition
Software Tools
- GraphPad Prism (dose-response curves)
- R or Python (advanced analysis)
- Excel (basic calculations)
- Plate reader software (raw export)
- LIMS or ELN (data management)
DATA TYPES IN MPS STUDIES
Continuous Data
Biomarker concentrations, TEER values, viability percentages, fluorescence intensity. Use parametric statistics (t-test, ANOVA) when normally distributed.
Functional Readouts
Beat rate, conduction velocity, calcium transients, barrier permeability. Often time-series data requiring specialized analysis approaches.
Imaging Data
Cell counts, morphological measurements, fluorescent areas. Requires image processing and feature extraction before statistical analysis.
Derived Metrics
IC50, EC50, therapeutic index, safety margins. Calculated from primary data using non-linear regression and propagated error estimation.
NORMALIZATION METHODS
| Method | Formula | Use Case | Advantages |
|---|---|---|---|
| % of Vehicle Control | (Sample / Vehicle Mean) × 100 | Toxicity assays, viability | Simple, intuitive interpretation |
| % of Positive Control | (Sample - Neg) / (Pos - Neg) × 100 | Efficacy screens, inhibition assays | Accounts for assay window |
| Z-Score | (Sample - Mean) / SD | Hit identification, cross-plate comparison | Standardizes across experiments |
| Per-Cell Normalization | Value / Cell Number (or DNA) | Secreted biomarkers, variable cell density | Corrects for seeding differences |
| Fold Change | Treated / Baseline | Time-course studies, pre/post comparison | Intuitive, logarithm-friendly |
| Robust Z-Score (MAD) | (Sample - Median) / (1.4826 × MAD) | Screens with outliers | Resistant to extreme values |
DOSE-RESPONSE CURVE FITTING
4-Parameter Logistic Model (4PL)
Y = Bottom + (Top - Bottom) / (1 + 10^((LogIC50 - X) × HillSlope))
Bottom
Minimum response (plateau at high drug concentration). For inhibition curves, typically 0% or residual activity.
Top
Maximum response (plateau at low/no drug). For inhibition curves, typically 100% of vehicle control.
IC50/EC50
Concentration producing 50% of maximal effect. Report with 95% CI. Use log scale (LogIC50) for fitting.
Hill Slope
Steepness of curve. Hill = 1 suggests simple binding. Hill > 1 indicates cooperativity; < 1 suggests heterogeneity.
Best Practices for Curve Fitting
- Use at least 6-8 concentrations spanning the full response range
- Space concentrations logarithmically (e.g., 3-fold or half-log dilutions)
- Include at least 2 concentrations on each plateau
- Fit to individual replicates first to assess variability, then to means
- Fix Top/Bottom only when biologically justified; prefer unconstrained fits
- Report R² (aim for > 0.9) and residuals should show no systematic pattern
- Compare IC50 values using extra-sum-of-squares F-test, not overlapping CIs
ASSAY QUALITY METRICS
Z' Factor (Zhang et al. 1999)
Z' = 1 - (3σSD_pos + 3σSD_neg) / |Mean_pos - Mean_neg|
- Z' > 0.5: Excellent assay
- 0 < Z' < 0.5: Marginal, may work
- Z' < 0: Assay not suitable for screening
Signal-to-Background (S/B)
S/B = Mean_signal / Mean_background
- Minimum S/B = 3 for reliable detection
- Higher S/B = better dynamic range
- Report alongside Z' for full picture
Coefficient of Variation (CV%)
CV% = (SD / Mean) × 100
- CV < 10%: Excellent reproducibility
- CV 10-20%: Acceptable
- CV > 20%: Needs optimization
Signal Window (SW)
SW = (Mean_pos - 3σSD_pos) - (Mean_neg + 3σSD_neg)
- SW > 0 required for hit detection
- Larger SW = more robust separation
- Alternative to Z' when distributions differ
STATISTICAL TEST SELECTION
| Comparison | Parametric Test | Non-Parametric Alternative | Post-hoc Test | When to Use |
|---|---|---|---|---|
| 2 Groups | Student's t-test (unpaired) | Mann-Whitney U | N/A | Treated vs vehicle |
| 2 Groups (paired) | Paired t-test | Wilcoxon signed-rank | N/A | Before/after on same samples |
| 3+ Groups | One-way ANOVA | Kruskal-Wallis | Tukey, Dunnett, Bonferroni | Multiple doses vs vehicle |
| 2 Factors | Two-way ANOVA | Friedman test | Šídök, Tukey | Dose × time, drug × genotype |
| IC50 Comparison | Extra-sum-of-squares F-test | N/A (use bootstrap) | N/A | Comparing potency between compounds |
Note: Use Dunnett's test when comparing multiple groups to a single control. Use Tukey's HSD for all pairwise comparisons. Apply Bonferroni correction for multiple testing when appropriate.
DATA ANALYSIS WORKFLOW
Data Import & Validation
Export raw data from plate reader. Verify all wells accounted for. Check for import errors (missing values, truncation). Match to plate layout template.
Quality Control Check
Calculate Z' factor using vehicle and positive controls. Verify CV% of controls < 15%. Check for edge effects (plot plate heatmap). Flag plates failing QC criteria.
Background Subtraction
Subtract blank wells (media only) from all readings. For plate-based effects, use per-plate blanks. Document blank locations and values.
Outlier Assessment
Apply Grubb's test or ROUT method to identify statistical outliers. Document criteria prospectively. Never remove outliers without documented justification. Retain all raw data.
Normalization
Express data as % of vehicle control (per plate). For cross-plate comparison, use Z-score or normalize to reference compound on each plate.
Curve Fitting (if dose-response)
Fit 4-parameter logistic model. Assess fit quality (R², residuals). Calculate IC50/EC50 with 95% CI. Compare curves using F-test if needed.
Statistical Testing
Apply appropriate tests (ANOVA, t-test). Correct for multiple comparisons. Report exact p-values and effect sizes. Use n = biological replicates for power.
Visualization & Reporting
Create publication-quality figures with all data points shown. Include error bars (SD or SEM with n stated). Document all analysis steps for audit trail.
💡 EXPERT TIPS
Biological vs Technical Replicates
Use n = independent experiments (different cell batches/days) for statistics, not replicate wells within a plate. Technical replicates show precision; biological replicates show reproducibility.
Log-Transform for IC50
Always fit dose-response on log scale. IC50 values are log-normally distributed. Report geometric mean and 95% CI. Compare IC50s as ratio (fold-change) not difference.
Don't Confuse Significance with Relevance
With enough replicates, tiny differences become "significant." Always report effect size. A 5% change may be p < 0.01 but biologically meaningless. Define meaningful thresholds upfront.
Show All Data Points
Bar graphs hide distribution. Use scatter plots or box plots with individual data points. Reviewers increasingly require this. Shows outliers, distribution shape, and true n.
SOFTWARE TOOLS
| Software | Best For | Key Features | Cost |
|---|---|---|---|
| GraphPad Prism | Dose-response curves, basic stats | 4PL fitting, IC50 comparison, publication figures | $250-500/yr |
| R (drc, ggplot2) | Advanced analysis, reproducible pipelines | Flexible modeling, scripted workflows, version control | Free |
| Python (scipy, pandas) | High-throughput, automation | Batch processing, ML integration, custom pipelines | Free |
| Genedata Screener | Industrial HTS | Plate normalization, QC, curve fitting, database | Enterprise |
| TIBCO Spotfire | Interactive visualization | Dashboards, exploratory analysis, linked views | Enterprise |
TROUBLESHOOTING
| Problem | Possible Causes | Solutions |
|---|---|---|
| Poor curve fit (low R²) | Insufficient concentration range, biphasic response, wrong model | Extend dose range, try biphasic model, check for partial agonism |
| IC50 outside tested range | Dose range too narrow, compound inactive | Extend range, report as "> highest dose tested" or "< lowest dose" |
| High inter-plate variability | Plate effects, inconsistent seeding, reagent batch | Normalize per-plate, include reference compound on each plate, standardize protocol |
| Low Z' factor | High control variability, small signal window | Optimize assay conditions, increase control replicates, use better positive control |
| Edge effects on plate | Evaporation, temperature gradients | Use perimeter wells for vehicle only, humidify incubator, apply edge correction algorithm |
| Wide confidence intervals | Low n, high variability, poor curve fit | Increase biological replicates (n = 3), reduce technical variability, verify assay performance |
| Non-monotonic dose-response | U-shaped response, compound aggregation, assay interference | Check solubility, use DLS for aggregation, test for assay interference, biological U-shape is real |
| Hill slope deviates from 1 | Cooperativity, multiple binding sites, receptor reserve | Report actual value, may indicate mechanism. Constrain to 1 only with justification |
| Results don't replicate | Cell batch variability, protocol drift, reagent lot | Include reference compound as internal standard, track lot numbers, standardize all steps |
| Statistical test assumptions violated | Non-normal distribution, unequal variance | Log-transform data, use non-parametric tests, Welch's correction for unequal variance |
FREQUENTLY ASKED QUESTIONS
Should I use SD or SEM for error bars?
SD (standard deviation) shows data spread/variability - use when you want to show the range of your data. SEM (standard error of mean) shows precision of the mean estimate - use when comparing means between groups. Always state which you're using and include n. For publication, showing individual data points + mean is often best.
What's the minimum n for regulatory submissions?
FDA typically expects n = 3 independent biological replicates (different passages, days, donors). IQ MPS consortium recommends n = 3 with demonstration of reproducibility across laboratories for qualification. More replicates improve confidence intervals and power. Report both number of independent experiments and technical replicates per experiment.
How do I compare IC50 values between compounds?
Don't compare overlapping confidence intervals - this is statistically incorrect. Use extra-sum-of-squares F-test in GraphPad Prism (compare: "Is one curve?"). This tests whether a single IC50 fits both datasets or whether they're significantly different. Report p-value and fold-difference in IC50.
When should I use non-parametric tests?
Use non-parametric tests when: (1) data is clearly non-normal (Shapiro-Wilk p < 0.05), (2) n < 10 per group (hard to assess normality), (3) data is ordinal or ranked, (4) significant outliers present. Common alternatives: Mann-Whitney U (for t-test), Kruskal-Wallis (for one-way ANOVA), Spearman (for Pearson correlation).
How do I handle values below detection limit?
Options: (1) Replace with LOD/2 or LOD/v2 - simple but biased; (2) Use censored data methods (Tobit regression); (3) If many values below LOD, consider the assay inappropriate for that range. Never use zero. Document your approach. For regulatory, discuss with statistician.
What's the difference between p-value and effect size?
p-value tells you probability of seeing your result if null hypothesis is true - it's affected by sample size. Effect size (Cohen's d, fold-change, R²) tells you magnitude of the difference - biologically meaningful. Always report both. A tiny difference can be "significant" with large n but meaningless. Define "biologically relevant" thresholds upfront.
Should I constrain Top and Bottom in curve fitting?
Default: let software estimate all 4 parameters. Constrain Top=100% only if you have solid vehicle controls demonstrating 100% baseline. Constrain Bottom=0 only if you observe complete inhibition. Improper constraints bias IC50. When reporting, state whether constrained and why. Check that unconstrained estimates are biologically plausible.
How do I correct for multiple comparisons?
More tests = more false positives. Bonferroni (divide a by number of tests) is conservative. Holm-Šídök is less conservative. For dose-response comparing to vehicle, use Dunnett's test (designed for this). For all pairwise, use Tukey's HSD. State correction method used. FDR (Benjamini-Hochberg) is popular for large screens.
What data should I include in regulatory submissions?
Include: (1) Raw data in structured format; (2) Analysis methods with software version; (3) QC metrics (Z', CV%); (4) All individual values, not just means; (5) Outlier criteria defined prospectively; (6) Complete statistical output; (7) Metadata (dates, operators, lot numbers). Follow FAIR principles. Audit trail must be complete and uneditable.
How do I calculate therapeutic index from MPS data?
TI = TC50 / EC50, where TC50 is toxicity concentration (50% cell death) and EC50 is efficacy concentration (50% target effect). Higher TI = safer. Compare to clinical Cmax: Safety Margin = TC50 / Cmax. Report with propagated confidence intervals. Values are model-dependent; compare within same platform only.
RELATED CONTENT
NEXT STEPS
- Establish QC criteria (Z' > 0.5, CV% < 15%) before starting experiments
- Create standardized templates for data import and plate layouts
- Validate normalization and analysis workflow with reference compounds
- Document all analysis procedures in SOPs for reproducibility
- Implement version control for analysis scripts (R/Python)
- Archive raw data with complete metadata for regulatory traceability